Kiniksa Pharmaceuticals, Ltd. (NASDAQ:KNSA) Given Consensus Recommendation of "Buy" by Analysts

Kiniksa Pharmaceuticals, Ltd. (NASDAQ:KNSA - Get Free Report) has earned a consensus rating of "Buy" from the five ratings firms that are covering the company, Marketbeat Ratings reports. Five analysts have rated the stock with a buy recommendation. The average 12 month target price among brokerages that have updated their coverage on the stock in the last year is $36.60.

A number of equities research analysts have issued reports on KNSA shares. Evercore ISI upped their price target on shares of Kiniksa Pharmaceuticals from $30.00 to $35.00 and gave the company an "outperform" rating in a report on Wednesday, October 30th. JPMorgan Chase & Co. boosted their price objective on Kiniksa Pharmaceuticals from $39.00 to $40.00 and gave the stock an "overweight" rating in a research report on Tuesday, November 5th. Finally, Jefferies Financial Group initiated coverage on Kiniksa Pharmaceuticals in a report on Friday, September 13th. They issued a "buy" rating and a $40.00 target price on the stock.

Kiniksa Pharmaceuticals Stock Performance

Kiniksa Pharmaceuticals stock opened at $22.04 on Wednesday. Kiniksa Pharmaceuticals has a 1-year low of $15.52 and a 1-year high of $28.15. The firm's fifty day simple moving average is $24.23 and its 200-day simple moving average is $22.91.

Kiniksa Pharmaceuticals (NASDAQ:KNSA - Get Free Report) last announced its earnings results on Tuesday, October 29th. The company reported ($0.18) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.01) by ($0.17). Kiniksa Pharmaceuticals had a negative return on equity of 7.31% and a negative net margin of 2.36%. The company had revenue of $112.21 million for the quarter, compared to the consensus estimate of $111.51 million. During the same period in the previous year, the company earned ($0.20) EPS. The firm's revenue for the quarter was up 67.4% compared to the same quarter last year. On average, research analysts predict that Kiniksa Pharmaceuticals will post -0.55 earnings per share for the current fiscal year.

Insider Buying and Selling

In other news, COO Eben Tessari sold 17,000 shares of the company's stock in a transaction dated Tuesday, October 15th. The shares were sold at an average price of $26.87, for a total value of $456,790.00. Following the sale, the chief operating officer now owns 109,975 shares of the company's stock, valued at approximately $2,955,028.25. This represents a 13.39 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, insider John F. Paolini sold 60,692 shares of the stock in a transaction dated Tuesday, September 3rd. The stock was sold at an average price of $26.12, for a total transaction of $1,585,275.04. Following the sale, the insider now owns 52,038 shares of the company's stock, valued at $1,359,232.56. This trade represents a 53.84 % decrease in their position. The disclosure for this sale can be found here. Insiders sold 95,192 shares of company stock valued at $2,479,390 over the last quarter. Corporate insiders own 54.57% of the company's stock.

Institutional Investors Weigh In On Kiniksa Pharmaceuticals

A number of hedge funds and other institutional investors have recently bought and sold shares of the business. Quarry LP acquired a new stake in shares of Kiniksa Pharmaceuticals in the third quarter valued at $50,000. CWM LLC grew its stake in shares of Kiniksa Pharmaceuticals by 443.0% during the third quarter. CWM LLC now owns 2,449 shares of the company's stock valued at $61,000 after purchasing an additional 1,998 shares during the last quarter. Lazard Asset Management LLC acquired a new stake in shares of Kiniksa Pharmaceuticals in the first quarter valued at approximately $71,000. nVerses Capital LLC bought a new position in Kiniksa Pharmaceuticals in the 3rd quarter worth approximately $80,000. Finally, Ashton Thomas Private Wealth LLC acquired a new position in Kiniksa Pharmaceuticals during the 2nd quarter worth $100,000. 53.95% of the stock is owned by institutional investors and hedge funds.

Kiniksa Pharmaceuticals Company Profile

Kiniksa Pharmaceuticals, Ltd., a biopharmaceutical company, focuses on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases with significant unmet medical needs worldwide. Its product candidates include ARCALYST, an interleukin-1alpha and interleukin-1beta, for the treatment of recurrent pericarditis, which is an inflammatory cardiovascular disease; Mavrilimumab, a monoclonal antibody inhibitor that completed Phase II clinical trials for the treatment of giant cell arteritis; Vixarelimab, a monoclonal antibody, that is in Phase 2b clinical trial for the treatment of prurigo nodularis, a chronic inflammatory skin condition; and KPL-404, a monoclonal antibody inhibitor of the CD40- CD154 interaction, a T-cell co-stimulatory signal critical for B-cell maturation, immunoglobulin class switching, and type 1 immune response.